We would love to hear your thoughts about our site and services, please take our survey here.
Timster said: ... the rest of what point have is garbage...
Not so. Point is using a different technology to target radiotherapy in cancer tumours. They have already sold some of the future cashflows for a couple of their potential drugs fir c$600 million.
Eli Lilly and Novo Nordisk have become the largest pharma companies in the world following the launch of their weight loss blockbuster drugs.
1 Eli Lilly
LLY
$510.99 B $538.29 0.22% 🇺🇸 USA
2 Novo Nordisk
NVO
$411.74 B $91.80 0.95% 🇩🇰 Denmark
3 Johnson & Johnson
JNJ
$373.60 B $155.15 0.39% 🇺🇸 USA
They are making so much money from them Barron’s lead article a couple of weeks ago they could bankrupt the US public healthcare system. Expect both to make acquisitions in the future.
Pharma companies developing drugs in the clinic have seen their share prices hit in the US recently because long term interest rates keep increasing as the US government’s deficit is so high to fund the chips act, the infrastructure act and the so-called inflation reduction act.
Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing. The transaction has been approved by the boards of directors of both companies.
The value of Point Biopharma shares are up 20 percent in the past week. Investors in the Nasdaq are not so sleepy as those on Aim.
The future of Avacta is being severely prejudiced by being quoted on Aim. The board should not delay in moving their share quote out of Europe and into New York.
The market cap is about $740 million. But the asset sale couldyet bring in more cash.
The strategy looks as if they were raising cash from the legacy assets to bet the ranch on Precision type radioligand therapies although I have not seen them say that.
Point do not do earnings calls. But they do talk at conferences. If you download the Quartr app you can listen to the audio for Point and other companies.
The cash and investment balance was $540 million at year end.
https://assets.website-files.com/61449a484d74b2708533bace/64218667cf4123031cb00c94_POINT%20Biopharma%20Investor%20Presentation%20(March%202023).pdf
This is the new slide presentation which refers to Canseek.
Comms is now a major governance issue. As is the perception of drift. Last year Avacta were sitting on their hands waiting for agents, partners and others to do work on the covid test was not being done.
Whatever the reason for the delay on announcing the next stage of the AVA6000 trials shareholders should be told what management are waiting for this time.
The comms, governance and drift issues are not doing shareholders or the Avacta share price any favours and add to the problems of the sleepy London share markets in general and the even more problematic Aim market in particular.
It is now clear Avacta will be acquired for pocket change in the near future and without the management putting up much of a defence. Whatever the major shareholders are doing to improve things are very much appreciated.
There are several concerns re the pension liabilities of Carclo.
1 LDIs have been used by some pension funds but which pose existential risks for them at the moment. In some cases pension funds have run leveraged exposure to interest rates. There could be massive losses if they close out these outsize risks by Friday as recommended by the Bank of England governor - or even more if they do not.
2 Carclo still run defined benefit pension schemes when most private sector companies switched them to defined contribution funds decades ago. These funds pose risks to companies like Carclo.
3 Carclo refers to some pension liabilities which are inflation adjusted. This means that pension liabilities could be up by 10 percent in the last year just because of these adjustments.
4 The Carclo pension fund paid out £9 million in pensions in a year when Carclo only made £3 million top-ups to the fund. The fund would therefore be £6 million short even if the pension fund had not lost money due to LDI risks or declining investment values - or if the fund liabilities had not increased due to UK inflation.